Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

BACKGROUND: How patients experience the symptoms/signs of psoriasis is highly relevant for assessing treatment response. OBJECTIVES: Compare outcomes with guselkumab, placebo and adalimumab utilizing the novel, validated Psoriasis Symptoms and Signs Diary (PSSD). METHODS: VOYAGE 1 is an ongoing, pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, K.A., Blauvelt, A., Kimball, A.B., Han, C., Randazzo, B., Wasfi, Y., Shen, Y.‐K., Li, S., Griffiths, C.E.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174988/
https://www.ncbi.nlm.nih.gov/pubmed/29512196
http://dx.doi.org/10.1111/jdv.14910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174988/
https://www.ncbi.nlm.nih.gov/pubmed/29512196
http://dx.doi.org/10.1111/jdv.14910

Ejemplares similares